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Objective: The earliest response of esophageal mucosa to gastric reflux is the devel-
opment of oxidative damage and inflammation. These processes contribute to the de-
velopment of metaplasia known as Barrett’s esophagus, as well as the progression to
malignancy. Secretory phospholipase A2 is a mediator of inflammation with levels
that are increased in Barrett’s metaplasia and carcinoma when compared with levels
in normal samples. Our goal is to determine the role of secretory phospholipase A2 in
the development of reflux-associated changes in the esophageal mucosa.
Methods: Secretory phospholipase A2–deficient mice (C57BL/6, n 5 5) and mice
known to express high levels of secretory phospholipase A2 (BALB/c, n5 5) under-
went side-to-side surgical anastomosis of the first portion of the duodenum and gastro-
esophageal junction, allowing exposure of esophageal mucosa to duodenal and gastric
contents duodeno-gastroesophageal anastomosis. Control animals (n 5 5) of each
strain underwent laparotomy with esophagotomy and repair. Tissue was frozen in em-
bedding medium. Hematoxylin and eosin staining and Ki67 and secretory phospholi-
pase A2 immunohistochemistry were used to evaluate esophageal tissue and its
response to duodeno-gastroesophageal anastomosis.
Results: Immunofluorescent staining confirmed the absence of secretory phospholi-
pase A2 in C57BL/6 mice and its presence in BALB/c mice. Hematoxylin and eosin
staining demonstrated significant thickening of the esophageal mucosa in response to
gastroesophageal reflux in the presence of secretory phospholipase A2. Mice known
to express high levels of secretory phospholipase A2 also demonstrated increased
numbers of proliferating cells. Secretory phospholipase A2–deficient mice were
immune to the early changes induced by mixed reflux.
Conclusions: The presence of secretory phospholipase A2 appears necessary for early
histologic changes produced by exposure of the esophagus to gastroduodenal con-
tents. This enzyme is identified as a promising target for evaluation of mechanisms
of carcinogenesis and chemoprevention of esophageal carcinoma.
T
he incidence of esophageal adenocarcinoma of the gastroesophageal junction
is rapidly increasing, and it is currently the cancer with the fastest-increasing
incidence in the United States. Since 1970, its incidence in some populations
has increased by more than 800%.1 Many possible risk factors, including obesity and
tobacco use, have been identified, but the most common risk factor is the increased
exposure of the esophagus to refluxed gastric contents.1 One case–control study esti-
mated that patients with long-standing severe gastroesophageal reflux disease
(GERD) were 43 times more likely to have adenocarcinoma of the esophagus.2
The actual mechanism by which GERD initiates the development of adenocarci-
noma is not proved but is thought to be the result of the development of the precursor
lesion Barrett’s esophagus.3 The development of Barrett’s esophagus because of
GERD has been attributed to multiple mechanisms, including alteration in gene ex-
pression levels caused by repeated injury during exposure of refluxed material and
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ANOVA 5 analysis of variance
DGEA 5 duodeno-gastroesophageal anastomosis
EGF 5 epidermal growth factor
GERD 5 gastroesophageal reflux disease
PBS 5 phosphate-buffered saline
sPLA2 5 secretory phospholipase A2
migration of gastric cardia tissue more proximally or by con-
ferring a competitive advantage to a mutant clone, allowing
a population of cells to predominate in the mucosa.3 The
study of the events that lead to the development of this pre-
neoplastic lesion can provide valuable insight into potential
treatments that might prevent the development of esophageal
adenocarcinoma.
The earliest response of esophageal mucosa to the pres-
ence of gastric reflux is the development of oxidative damage
and inflammation.4 Inflammation is manifested in several
ways, including alterations in cytokine production, infiltra-
tion of inflammatory cells, and upregulation of inflammatory
mediators. Histologic evidence of exposure of esophageal
mucosa to reflux includes basal cell hyperplasia, acanthosis
(or thickening of the squamous epithelium), and eosinophilic
infiltration of the mucosa.5
Given the widely established link between the mucosal in-
jury produced by GERD and the development of both Bar-
rett’s esophagus and carcinoma, the study of mediators of
this inflammatory response has been intense. Molecules,
such as cyclooxygenase-2,6 nuclear factor kB,7 and tumor ne-
crosis factor a,8 have been studied extensively regarding their
role in esophagealmucosal inflammation. Recently, the group
of phospholipase A2 enzymes
9 has been implicated as amedi-
ator of intestinal inflammation and identified as playing a pos-
sible role in tumor development. This group of enzymes is
responsible for liberating arachidonic acid from phospho-
lipids for eicosanoid production (Figure 2). A subtype of
this group, group IIa secretory phospholipase A2 (sPLA2),
is thought to play a significant role in the pathogenesis of in-
flammatory bowel disease.10 Levels of sPLA2 have also been
shown to be increased in samples of human Barrett’s esopha-
gus, as well as adenocarcinomas, comparedwith levels in nor-
mal mucosa, indicating a potential role of sPLA2 in the
development of both of these pathologic lesions.11
A report by Kennedy and colleagues12 first demonstrated
that several species of inbred mice have a disruption in the
sPLA2 gene.
12 The occurrence of a naturally occurring mu-
rine knockout model has led to investigation into the possible
role that sPLA2 plays in cellular function. Insights gained
from these studies have demonstrated that sPLA2 might
play a role in apoptosis in gastric mucosal cells13 and contrac-
tile function of cardiac muscle,14 as well as influencing anti-The Journal of Thorgen-presenting cell–mediated intestinal tumorigenesis.15 We
report our observations regarding the influence of the pres-
ence of sPLA2 on the early response of esophageal mucosa
to gastroduodenal reflux in a murine model.
Materials and Methods
Generation of Gastroduodenal Reflux in a Murine
Model
Eight-week-old BALB/c (n 5 12) and C57BL/6 (n 5 10) mice
(Jackson Labs, Bar Harbor, Me) aged 8 to 12 weeks and weighing
18 to 22 g were fed regular chow (Harlan Teklad #2018, Madison,
Wis) and water ad libitum. Animals were allowed to acclimatize for
10 days before surgical intervention. Animals were fasted but allowed
access to water for 24 hours before the experimental procedure. Mice
were anesthetized by means of the intraperitoneal injection of ket-
amine (80 mg/kg; Fort Dodge Animal Health, Fort Dodge, Iowa)
and xylazine (12 mg/kg; VEDCO, St Joseph, Mo). Body temperature
was monitored rectally and maintained at 36.5C by using a heating
lamp. Under sterile conditions and with the aid of an operating micro-
scope (Leica MZ95, Wetzlar, Germany), a side-to-side anastomosis
was performed between the first portion of the duodenum and the
gastroesophageal junction by using 10-0 nylon sutures (duodeno-
gastroesophageal anastomosis; n 5 7 BALB/c mice; n 5 5 C57BL/
6 mice; Figure 1).16 Animals were then recovered under a heating
Figure 1. Schematic representation of the surgical model of
creating mixed gastroduodenal (DGEA) reflux.acic and Cardiovascular Surgery c Volume 135, Number 6 1221
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with incision and closure of the esophagus superior to the gastro-
esophageal junction without anastomosis (n5 5 in each strain). An-
imals then were fed ad libitum andweighed weekly tomonitor weight
gain. The Animal Care and Use Committee at the University of Col-
orado at Denver Health Sciences Center approved the protocol to per-
form the necessary survival operation and tissue harvesting for this
project (protocol no. 77205206[05]1E).
Tissue Harvesting
Themice were sacrificed 28 days after surgical induction of gastrodu-
odenal reflux by using inhaled carbon dioxide. The entire esophagus
and stomachwere then removed andflushedwithOCTmedium (OCT
Tissue-Tek, Torrance, Calif). Care was taken to identify and use only
tissue above the anastomosis for study. Three segments of tissue cut in
5-mm lengths originating just above the anastomosis were then cut,
embedded in OCTmedium, and frozen in a way that would allow ax-
ial sectioning of the esophageal lumen. Serial 5-mmsectionswere then
mounted onto glass slides for histologic analysis. This study presents
data obtained only from the blocks that were closest to the anastomo-
sis, thus comparing the same segment from all animals.
Morphologic and Immunohistochemical Analysis of
Esophageal Tissue
Hematoxylin and eosin staining was performed to evaluate mucosal
morphology. Four digital images taken around the circumference of
each specimen were acquired, and 3 measurements of mucosal
thickness were made at equal intervals within each digital image
by a blinded observer. Data were compared by means of analysis
of variance (ANOVA) with the post-hoc Tukey test.
Detection of sPLA2 Protein in Esophageal Tissue by
Using Immunofluorescence
Esophageal tissue frozen in OCT medium was cut and placed on
slides. Slides were then fixed in acetone/methanol (1:1), blocked in
5% donkey serum containing 1% albumin in phosphate-buffered sa-
line (PBS), and then incubated with a polyclonal antibody to human
sPLA2 (goat anti-human antibody; Santa Cruz Biotechnology, Santa
Cruz, Calif) in a dilution of 1:50 in 1% albumin/PBS for 1 hour at
Figure 2. Diagram demonstrating the role of secretory phospholi-
pase A2 (sPLA2) in the arachidonic acid pathway.1222 The Journal of Thoracic and Cardiovascular Surgery c Juroom temperature. After washing in PBS, the slides were then incu-
bated with a Cy3-conjugated Donkey anti-goat antibody (Jackson
Immunoresearch, West Grove, Pa) in a 1:150 dilution for 45 minutes
at room temperature, washed, and placed under coverslips over anti-
quenching medium. Visualization of staining for sPLA2 was per-
formed on a Zeiss confocal microscope (Thornwood, NY).
Identification of Proliferating Cells by Using Ki67
Immunohistochemistry
Endogenous peroxidase activity was blocked by incubating slides
for 10 minutes in 0.3% H2O2 in methanol. Slides were then fixed
in acetone/methanol (30:70) for 5 minutes. After washing in PBS,
slides were fixed with 4% paraformaldehyde for 10 minutes. Anti-
gen retrieval was performed with a citrate buffer bath for 20 minutes.
Slides were then bathed in distilled water and washed in PBS. Slides
were then incubated in 5% blocking serum with 0.3% Triton in PBS
(sheep or rabbit) for 30 minutes. Samples were then incubated in
rabbit polyclonal antibody to Ki67 (NovusBio, Littleton, Colo)
1:25 in 0.3% Triton in PBS for 12 hours at 4C. After washing in
PBS 3 times, the slides were incubated with a biotinylated sheep
anti-rabbit secondary antibody (Serotec, Raleigh, NC) 1:250 with
0.3% Triton in PBS for 1 hour at room temperature. After washing
in PBS and incubating in horseradish peroxidase complex for 30
minutes, slides were developed with 3,30-diaminobenzidine. Four
digital images of each of 3 esophageal segments for each animal
were acquired by using a 403 objective. In each image the total
number of cells in the esophageal mucosa with nuclei that stained
positive for Ki67 was counted by a blinded observer.
Statistical Methods
Data were compared by means of ANOVAwith the post-hoc Tukey
test.
Results
Outcome of Surgical Procedure and Health of Mice
Overall, 90% of the animals survived the procedures and
study period. Two of the 7 BALB/c mice died perioperatively
after the study (duodeno-gastroesophageal anastomosis) pro-
cedure, and no animals died either after the sham procedure
or during the period of 24 hours after surgical intervention
and the 28-day end point of the experiment. The 2 animals
that died might have died of excessive anesthesia, hemor-
rhage, or intestinal ischemia, but a definitive cause was not
recognized. The mean body weights in all of the animal
groups were not significantly different at the end of the study
period (C57BL/6 mice, P5 .87; BALB/c (DGEA) mice, P5
.39; Table 1). The BALB/c duodeno-gastroesophageal anas-
tomosis mice initially have slower weight gain but recover to
normal at least 2 weeks before the end of the study period.
The animals appeared grossly normal at the termination of
the experiment. On visual inspection of the esophageal tissue
after harvest, there grossly did not appear to be any differences
among the study groups. Tumor tissue was not grossly iden-
tified in any of the specimens. The anastomotic areas in all
DGEA animals were identified to be patent, as demonstrated
by passing a probe through the anastomosis in each animal.ne 2008
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that underwent sham operations and those undergoing reflux operations
Week 0 Week 1 Week 2 Week 3 Week 4
BALB/c DGEA 22.9 6 0.69 22.1 6 0.98 22.6 6 0.93 23.9 6 1.00 26.3 6 0.80
BALB/c CTRL 23 6 0.46 23.5 6 0.69 24.24 6 0.67 25.5 6 0.68 26.1 6 0.67
C57BL/6 DGEA 20.8 6 0.79 22.6 6 0.44 23.36 6 0.25 24.9 6 0.24 25.5 6 0.41
C57BL/6 CTRL 20.8 6 0.33 22.8 6 0.15 22.8 6 0.32 24.5 6 0.43 25.3 6 0.43
P values for week 4 are shown in the text. DGEA, duodeno-gastro esophageal anastomosis; CTRL, control.Microscopic Analysis of Esophageal Tissue
We evaluated by means of immunofluorescence the presence
of the sPLA2 protein in esophageal tissue in the study ani-
mals. We clearly identified the presence of sPLA2 in the
esophageal mucosa of BALB/c mice, but the C57BL/6
mice had no identifiable sPLA2 in esophageal mucosa
when compared with the negative control animals (Figure 3).
Microscopically, DGEA induced observable changes in
the esophageal mucosa of BALB/c, sPLA2
1/1 mice (P ,
.0001, ANOVA). These changes included a significant thick-
ening of the mucosal layer similar to that described in human
subjects (BALB/c DGEA mice vs BALB/c sham mice: P #
.001).17 These changes were most clearly evident in the 5 mm
of esophagus immediately superior to the anastomotic area
(which is the data presented in this study). The changes
appeared to dissipate in a graded fashion, moving more prox-
imally in the esophagus (data not shown). Epithelial thick-
ness was not significantly different in the sPLA2
2/2
C57BL/6 mice with surgically induced reflux (C57BL/6
DGEA mice vs C57BL/6 sham mice: P 5 .47, Tukey post-
hoc test), with no significant microscopic changes seen bymeans of hematoxylin and eosin staining in any portion of
the esophagus compared with that seen in control animals,
thus indicating the potential role that this enzyme might
play in these mucosal changes (Figure 4). Evaluating the
presence of proliferating cells through the use of Ki67 stain-
ing demonstrated that the BALB/c mice had a significant in-
crease in the number of proliferating cells when compared
with the control animals (P , .0001 [ANOVA] and P ,
.001 [Tukey post-hoc test] for BALB/c DGEA mice vs
BALB/c sham mice). These proliferating cells appeared to
be most prominent in the basal layers, which is a consistent
pathologic finding in human gastroesophageal reflux.17
Again, there was no significant difference between the treat-
ment and control groups in the sPLA2 null mice (P5 .22, Tu-
key post-hoc test, for C57BL/6 DGEA mice vs C57BL/6
sham mice; Figure 5).
Discussion
Histologic changes that are produced in response to gastrodu-
odenal reflux include thickening (acanthosis) of the mucosa,Figure 3. Immunofluorescence analysis
of DGEA esophageal tissue in study an-
imals demonstrating no identifiable
protein in C57BL/6 mice and identifiable
secretory phospholipase A2 (sPLA2) pro-
tein (red staining) in BALB/c mice (A)
compared with that seen in negative
control animals (B).
The Journal of Thoracic and Cardiovascular Surgery c Volume 135, Number 6 1223
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TSFigure 4. Hematoxylin and eosin analy-
sis of mucosal thickness at 203magnifi-
cation. Significant increase in mucosal
thickness in response to DGEA inBALB/c
secretory phospholipase A2 (sPLA2)1/1
mice (n 5 5; A) compared with C57BL/6
sPLA2
2/2 mice (n5 5; B) is shown.hyperproliferation, and eosinophilic infiltration.5,17 Here we
have shown in a murine model that histologic changes in re-
sponse to gastroduodenal reflux are similar to those seen in
human and other animal models. The model we have adapted
was originally described to produce esophageal adenocarci-
noma and changes similar to Barrett’s esophagus in rats
over a 40-week period.16 We have previously demonstrated
that the technical aspects of the same model can be success-
fully applied in mice (Babu andWeyant and associates, man-
uscript in preparation), and our observations show that with
the introduction of the DGEA, there is no significant alter-
ation in such nutritional parameters as food intake andbody weight during the study period. The time period of 4
weeks was chosen to allow the dissolution of the effects of
surgical intervention and healing on the esophageal mucosa,
yet provide an opportunity to observe the early effects of
reflux.
In this study we have demonstrated that histologic
changes caused by gastroduodenal refluxmight be influenced
by the genetic background of the host animal.We take advan-
tage of a naturally occurring disruption of the sPLA2 gene
that occurs in C57BL/6 mice and use it to study the effects
of the presence of this enzyme during stimulation of esopha-
geal mucosa with DGEA by comparing them with BALB/cFigure 5. Ki67 immunohistochemistry
demonstrating a significant increase
in proliferating cells in response to
DGEA in BALB/c secretory phospholi-
pase A2 (sPLA2) 1/1 mice (n 5 5; A)
compared with C57BL/6 sPLA2
2/2 mice
(n 5 5; B). Black arrowheads point to
some of the positive nuclei as an
example. HPF, High-powered field.
1224 The Journal of Thoracic and Cardiovascular Surgery c June 2008
Babu et al General Thoracic Surgery
G
TSmice known to express high levels of the enzyme. The con-
venience of a naturally occurring disruption of the sPLA2
gene has led to several observational studies comparing these
2 strains of mice, demonstrating functional differences in
such areas as cardiac contractile function and susceptibility
to the development of intestinal tumorigenesis.14,15
The most well-described role of the group of sPLA2 en-
zymes is to catalyze the hydrolysis of membrane phospho-
lipids, leading to the generation of arachidonic acid, thus
providing the substrate for inflammatory mediators, such as
prostaglandins and leukotrienes.18 The induction and overex-
pression of sPLA2 enzymes are implicated in a variety of
pathologic processes, such as septic shock and inflammatory
bowel disease.18 It is not surprising that there is significant
interaction with other known pathogenic enzymes, such as
cyclooxygenase-1 and -2.
Our observations suggest that sPLA2 might play a role in
regulating esophageal mucosal growth and the hyperplasia
produced by GERD. The role of sPLA2 as a potential
growth-regulating protein is demonstrated in other in vivo
and in vitro models. Grass and colleagues19 reported that in
the same C57BL/6 mouse with human group IIa sPLA2 rein-
troduced into the genome, there was epidermal hyperplasia at
baseline, indicating an effect of the reconstituted enzyme on
cell proliferation, apoptosis, or both. Other in vitro studies
have demonstrated that arachidonic acid metabolites are re-
quired for epidermal growth factor (EGF)–mediated cell pro-
liferation.20,21 This is important considering that EGF/EGF
receptor signaling is an important pathway regulating cell
proliferation in the esophageal mucosa.22 In macrophages
sPLA2 has been demonstrated to mediate phosphorylation
of Akt, which leads to a downstream growth regulatory effect
in these cells.23 In murine small intestinal tissue an sPLA2–
like molecule has been shown to bind to EGF and influence
cell proliferation.24 Given the reported role of the EGF recep-
tor in all types of esophageal carcinoma, this represents an
important relationship to be studied in this model.25 In human
subjects the observation that levels of this enzyme are in-
creased in both Barrett’s mucosa and esophageal adenocarci-
noma indicates a possible role of sPLA2 in growth and
metaplastic transformation of these cells.11 Characterization
of the presence of sPLA2 activity, as well as downstream me-
diators, in these animal strains exposed to reflux will be an
important direction of future study to make a mechanistic
link to epithelial growth regulation.
We demonstrate that mice with an intact sPLA2 gene ap-
pear to have an enhanced development of histologic changes
associated with gastroduodenal reflux as early as 4 weeks
after the surgical induction of reflux. Importantly, we demon-
strate the ability to identify the sPLA2 protein in esophageal
tissue in BALB/c mice, as well as showing its absence in the
C57BL/6 mice by means of immunofluorescence. Recent
studies using other methods of detection have not demon-
strated high levels of this protein in BALB/c esophageal tis-The Journal of Thorasue. The ability to clearly identify the presence of the enzyme
in our study animals might indicate the finding that the en-
zyme is upregulated in response to surgical intervention. Fur-
ther studies to clarify this finding are underway.26 The
relevance of histologic changes seen in this model with re-
spect to Barrett’s esophagus, as well as esophageal carci-
noma, remain unknown. However, in similar rodent models
the progression from epithelial hyperplasia to Barrett’s meta-
plasia has been demonstrated, suggesting that these are
indeed clinically significant changes.27
Given the available data demonstrating the presence of
this genetic anomaly, it would be unwise to assume that
this might be the only contributing factor to the epithelial
changes seen here. Nonetheless, these findings allude to the
involvement of sPLA2 in the manifestation of histologic
changes early in the response to DGEA. This murine model
also demonstrates significant utility in the study of hyperplas-
tic changes related to reflux. Our findings highlight sPLA2 as
a potential agent to be studied in the treatment of GERD, as
well as chemoprevention of esophageal cancer.
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Discussion
Dr Steven DeMeester (Los Angeles, Calif). I would like to congrat-
ulate Dr Weyant and his colleagues both for an excellent presenta-
tion and a very clearly written manuscript.
In this study the authors evaluated the role of sPLA2 in a mouse
model of surgically induced gastroduodenoesophageal reflux. By
using an inbred mouse strain deficient in the gene for phospholipase
A2, they were able to ascertain the role of this enzyme in early
esophageal mucosal changes associated with reflux. Compared
with normal mice, the knockout mice showed significantly less in-
crease in epithelial thickness and in Ki67 activity, with levels in
the knockout mice equivalent to those in control animals. They con-
clude that phospholipase A2 is involved in the early squamous mu-
cosal changes associated with gastroduodenoesophageal reflux.
The authors are to be congratulated for several things. First, they
successfully developed this mouse model of surgically induced1226 The Journal of Thoracic and Cardiovascular Surgery c Jureflux, which has been a hurdle for many investigators in the past.
Second, they demonstrate that the phospholipase A2 protein can
be found in esophageal tissue in the mouse. Third, they designed
an elegant first experiment by using a mouse knockout model for
this gene to demonstrate the role of phospholipase A2 in early squa-
mous esophageal mucosal injury associated with reflux. I have 3
questions for you.
First, changes in esophageal mucosal thickness or the old (Ish-
mael Bagay) criteria for reflux are known to be quite nonspecific.
Recent work by Ray Orlando and colleagues using transmission
electron microscopy to look at dilated intracellular channels sug-
gests that this might represent a very sensitive and specific way to
assess early mucosal changes associated with reflux. Have you con-
sidered using transmission electron microscopy to evaluate in the
mouse the presence or absence of these dilated intracellular chan-
nels?
DrWeyant. I am aware of the technique, but at our institution, it
is difficult to achieve the use of that specific technique, although it is
something that we are certainly interested in looking at in the future.
Dr Demeester. Second, the really significant (ie, premalignant)
changes that occur with reflux involve the transformation of the
squamous esophageal mucosa to columnar cardiac mucosa and
then subsequently to intestinal metaplasia. Do you anticipate that
with a longer duration of reflux in this mouse model that these his-
tologic changes will occur? In other words, can you replicate in the
mouse model what has been shown to occur in the rat model of gas-
troduodenoesophageal reflux?
DrWeyant. I believe we can. I am certainly very optimistic that
we can. Even after 4 weeks in some of these mice, we are actually
able to see changes that appear to be the early morphologic changes
consistent with Barrett’s esophagus. I did not have the time to show
the slides here, but our next phase of these studies is going to be to
take these mice and reflux them for several weeks, up to 40 weeks,
and harvest the mice at several different time periods so that we have
the whole spectrum of carcinogenesis of gastroesophageal junction
adenocarcinoma; that will then allow us to study all of these molec-
ular markers at these different time points in this model, as well as
using the similar model in other genetic backgrounds, such as
a P53 knockout mouse and others that are available, where we can
apply this model now that we are proficient in it.
Dr Demeester. Lastly, although there is no doubt that a link be-
tween inflammation and cancer exists, the nature of that relationship
is very complex. Rebecca Fitzgerald, in addition to work from our
own laboratory, has shown that there is an inflammatory gradient
within Barrett’s esophagus with maximal expression of inflamma-
tory genes proximally in a Barrett’s esophagus segment, yet many
of the cancers occur distally in areas with much lower levels of in-
flammatory gene expression. In light of this, can you give us your
thoughts on the role of phospholipase A2 and what its role might
be in carcinogenesis within Barrett’s esophagus? Do you think it
is an early mediator of progression in Barrett’s esophagus or merely
a marker for injury?
Congratulations again and thank you for the opportunity to dis-
cuss this paper.
Dr Weyant. Thank you very much for your comments, Dr De-
Meester.
Part of our next phase of these studies also goes along with what
our next main hypothesis is regarding the function of sPLA2 in thatne 2008
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TSour initial observations showed of these quick and dirty findings of
hyperplasia and thickening of the mucosa, but what that really points
to for me is that sPLA2 is somehow a growth regulator in esophageal
mucosa. Some of the articles I have listed on one of the previous
slides are some of the less well-known literature regarding sPLA2,
and not one of them has sort of hit on the main point that it interacts
with EGF receptor and its ligand, whichwe know is already a growth
factor in esophageal mucosa, as well as other growth factors. Again,
these are reported in other tissues using different models, but I think
our next step is to apply those hypotheses to this model to see really
how sPLA2 acts as a growth factor in esophageal mucosa, and I think
we will.
Doctor. I have a quick follow-up question for you, which speaks
to my inherent suspicion of knockout mice. Can you comment more
on these collateral secretory phenotypic changes associated with the
black-6 mouse? In other words, I appreciate that your inhibitor stud-
ies validate that phospholipase A2 is at least a necessary cofactor inThe Journal of Thorathis preparation, but are there any other changes that result from this
particular genetic variation as relates to acid or bile salt excretion?
DrWeyant. As far as other experience goes, no. That is a contin-
ual concern of ours, and data that I did not present here that we have
also recently accumulated in the laboratory—there is actually
a mouse available with a black-6 background that has the sPLA2
gene reintroduced into it. Whenwe do this samemodel here compar-
ing a black-6 wild-type mouse and a black-6 mouse that has the
sPLA2 gene reintroduced, we get the same findings of the hyperpla-
sia and thickening of mucosa. Between the inhibitor studies and
what we call the ‘‘knock-in’’ studies, that is as confident as I can
be that we are actually seeing a real change here. The reason we
went to these lengths of using the inhibitor study and the knock-in
mouse was because of those concerns that we shared also.
Doctor. I agree. Excellent job. Elegant work, and everybody on
the project should be commended on technically pulling this off.
That is a real feat of technical expertise. Congratulations.cic and Cardiovascular Surgery c Volume 135, Number 6 1227
